LUIS ALBERTO
MENCHÉN VISO
Profesor asociado de Ciencias de la Salud
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (13)
2024
-
Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus
BMJ Open Gastroenterology, Vol. 11, Núm. 1
2023
-
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP
Journal of Clinical Medicine, Vol. 12, Núm. 14
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
-
Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review
Journal of Clinical Medicine, Vol. 12, Núm. 23
2022
-
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83
2021
-
Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing
European journal of gastroenterology & hepatology, Vol. 33, Núm. 1S Suppl 1, pp. e796-e802
-
Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu
Journal of Clinical Medicine, Vol. 10, Núm. 19
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
2011
-
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience
Gastroenterologia y Hepatologia, Vol. 34, Núm. 7, pp. 443-448
2008
-
Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis
Alimentary Pharmacology and Therapeutics, Vol. 28, Núm. 5, pp. 623-628
-
Open-label infliximab therapy in Crohn's disease: A long-term multicenter study of efficacy, safety and predictors of response
Gastroenterologia y Hepatologia, Vol. 31, Núm. 7, pp. 421-426